Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HERCULES

Financiado

Cerrado

Comprehensive characterization and effective combinatorial targeting of high gra...

Comprehensive characterization and effective combinatorial targeting of high grade serous ovarian cancer via single cell analysis The goal of this multidisciplinary project is to comprehensively characterise high-grade serous ovarian cancer (HGS-OvCa) at single-cell level, identify the best combination of drug combination to kill HGS-OvCa populations and co... ver más

30/06/2021

HELSINGIN YLIOPIST...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

HELSINGIN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 12 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-06-30

PHC-02-2015: Understanding disease: systems medi...

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

HELSINGIN YLIOPISTO

2.45M€ | Lider

PERNILS LLEMENA

185.66K€ | Participante

ROSER CONSTRUCCIONES METALIC...

309.68K€ | Participante

UNIVERSITY OF TURKU

999.21K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MaCaROM Mapping Cancer Response using Organoids and Mass cytometry 191K€ Cerrado

DECIDER Improved clinical decisions via integrating multiple data le... 15M€ Cerrado

FPSA13-1E-2048 Integrando la Medicina de Precisión a Nivel de la Célula Ind... 1K€ Cerrado

SENSITIVITYMARKERS Clinical validation of prognostic biomarkers of chemotherapy... 71K€ Cerrado

CTCPROTEOMIC Single cell proteomics for studying circulating tumor cells... 200K€ Cerrado

MR O MICS Unravelling Tumour Biology In Ovarian Cancer With Precision... 1M€ Cerrado

Duración del proyecto: 66 meses Fecha Inicio: 2015-12-02
Fecha Fin: 2021-06-30

Líder del proyecto

HELSINGIN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The goal of this multidisciplinary project is to comprehensively characterise high-grade serous ovarian cancer (HGS-OvCa) at single-cell level, identify the best combination of drug combination to kill HGS-OvCa populations and commercialise a predictive biomarker kit for finding the right therapeutic regimen to the right patient. This project takes an advantage on prospectively and longitudinally collected fresh sample specimens from multiple anatomic sites of HGS-OvCa patients with metastatic disease. Fluorescence activated cell sorting and recently developed mass cytometry are used to identify subpopulations in HGS-OvCa tumors. This is followed by single-cell analysis at genetic and transcriptomics levels, and ex vivo drug screening experiments. These data will be used to establish network models to predict the most effective combinatorial treatments. The key results will be validated with existing HGS-OvCa data together with prospective and retrospective cohorts and in vivo models. The clinically most actionable treatment suggestions from our modelling efforts will be translated to HGS-OvCa patient care. Ovarian cancer kills more than 40,000 women in Europe every year due to lack of effective and long-lasting therapeutic regimens. HERCULES presents an innovative strategy to suggest effective treatments that lead to a marked decrease in ovarian cancer deaths and reduce the number of expensive but inefficient treatments. Our approach paves the way to move beyond the current trial-and-error clinical assessment of drug combinations toward more systematic prediction of the most effective drug combinations for each patient. The proposed approach will be a major breakthrough in systems medicine and will benefit individual ovarian cancer patients and the health-care system through more effective treatments, and the diagnostic and pharmaceutical industry through tools for better stratified clinical trials, and novel treatment and diagnostic modalities.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores